Lymphoma, T-Cell, Peripheral: all 607 studies
Page 2 of 7. Open to participants first (133), then studies with results posted, then the rest; newest registration first within each.
- Genotype-guided Treatment in Newly Diagnosed PTCLRecruitingNCT05675813Phase 1/2
- PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell LymphomaRecruitingNCT05662540Not applicable
- Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT05572983Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaNot yet recruitingNCT05458180Phase 1
- Transplantation After Complete Response In Patients With T-cell LymphomaRecruitingNCT05444712Not applicable
- Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCLRecruitingNCT05441761Phase 1/2
- The Whole-course Management of Pegaspargase in ENKTLNot yet recruitingNCT05426824Not applicable
- Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell LymphomaRecruitingNCT05367856Phase 2
- A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell LymphomaNot yet recruitingNCT05343377Not applicable
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
- Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)RecruitingNCT05230680Phase 1/2
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
- Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell LymphomaRecruitingNCT05075460Phase 3
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical StudyRecruitingNCT04880746Phase 3
- Expanded Access to TipifarnibAvailableNCT04809233
- Prognostic Nomogram of Extranodal NK/T-cell LymphomaRecruitingNCT04554511
- Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaRecruitingNCT04512534Phase 2
- The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell LymphomaRecruitingNCT04489264
- Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell LymphomaRecruitingNCT04484506Phase 2
- Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell LymphomaRecruitingNCT04414969Phase 2
- Evaluate the Safety and Clinical Activity of HH2853RecruitingNCT04390737Phase 1/2
- A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)RecruitingNCT04365036Phase 3
- Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 1
- Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaRecruitingNCT04128072Phase 2
- CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaRecruitingNCT04083495Phase 2
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingNCT04068597Phase 1/2
- Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCLNot yet recruitingNCT04052659Phase 2
- A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaRecruitingNCT04045470Not applicable
- Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.RecruitingNCT03964480
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingNCT03719105Early Phase 1
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLTerminatedNCT05883449Phase 2Results posted
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaCompletedNCT05380635Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
- AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHLCompletedNCT05140382Phase 2Results posted
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingNCT04703192Phase 2Results posted
- A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionCompletedNCT04569032Phase 2Results posted
- Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
- Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
- Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFHTerminatedNCT04251065Phase 2Results posted
- Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"CompletedNCT04213209Results posted
- Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
- Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis FungoidesCompletedNCT04101331Phase 2Results posted
- A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
- Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCompletedNCT03927105Phase 2Results posted
- Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompletedNCT03905135Phase 1Results posted
- Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaCompletedNCT03770000Phase 1/2Results posted
- SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedNCT03713320Phase 2Results posted
- A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedNCT03595657Phase 2Results posted
- Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasCompletedNCT03586999Phase 1/2Results posted
- Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)TerminatedNCT03547700Phase 1/2Results posted
- CC486-CHOP in Patients With Previously Untreated Peripheral T-cell LymphomaCompletedNCT03542266Phase 2Results posted
- Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaCompletedNCT03534180Phase 2Results posted
- Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 2Results posted
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT03372057Phase 2Results posted
- A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCLCompletedNCT03349333Phase 3Results posted
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT03292406Phase 2Results posted
- Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
- T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasCompletedNCT03049449Phase 1Results posted
- Avelumab in Relapsed and Refractory Peripheral T-cell LymphomaCompletedNCT03046953Phase 2Results posted
- Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)CompletedNCT02955589Phase 2Results posted
- Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT02953652Phase 2Results posted
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
- Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
- A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT02653976Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac DiseaseCompletedNCT02633020Phase 2Results posted
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaCompletedNCT02567656Phase 1Results posted
- Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/2Results posted
- Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin LymphomaTerminatedNCT02535247Phase 1/2Results posted
- Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyCompletedNCT02464228Phase 2Results posted
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)CompletedNCT02448381Phase 3Results posted
- A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
- Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results posted
- Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
- Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaTerminatedNCT02314247Phase 2Results posted
- Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell LymphomaCompletedNCT02296164Results posted
- Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationCompletedNCT02273739Phase 1/2Results posted
- ALRN-6924 in Patients With Advanced Solid Tumors or LymphomasCompletedNCT02264613Phase 1/2Results posted
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
- Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasCompletedNCT02158975Phase 2Results posted
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedNCT01871727Phase 3Results posted
- Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30TerminatedNCT01841021Not applicableResults posted
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
- Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma PatientsCompletedNCT01822886Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedNCT01804166Phase 4Results posted
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
- CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaTerminatedNCT01746173Phase 2Results posted
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLCompletedNCT01728805Phase 3Results posted
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results posted
- Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
- Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedNCT01676831Phase 1/2Results posted
- Treatment of Peripheral T-cell LymphomaCompletedNCT01664975Phase 4Results posted
- Everolimus in Treating Cutaneous T-cell LymphomaTerminatedNCT01637090Phase 2Results posted
- A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaCompletedNCT01614197Phase 1Results posted
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted